India's National Pharmaceutical Pricing Authority issued an order on October 17 extending trade-margin rationalization to 137 non-scheduled oncology medicines.
The measure caps distribution and retail trade margins at 30% of maximum retail price, excluding applicable taxes, and is expected to reduce some prices by up to 70%. Covered medicines include pembrolizumab, durvalumab, osimertinib, bevacizumab, and other oncology treatments.
Manufacturers must report revised prices within seven days, while pharmacies and hospitals must implement the new prices beginning November 9, 2026. The intervention follows a 2019 program covering 42 oncology medicines. Reuters
Sources: Reuters — October 18 · Indian government notification text · NPPA official website
Why it matters strategically
The most important distinction is between manufacturer revenue and downstream distribution margins.
The intervention primarily targets the difference between the manufacturer's selling price and the final retail price.
It does not automatically impose a 70% reduction on the revenue manufacturers receive.
Under the regulatory formula, a trade margin of 30% of retail price corresponds to a maximum markup of approximately 42.86% over the price to the stockist or distributor.
Consider the example included in the regulatory materials.
A medicine has a manufacturer-to-distributor price of ₹70 and an existing retail price of ₹300.
Under the new formula, the maximum retail price becomes approximately ₹100 before applicable taxes.
The patient's price falls by approximately 66.7%, while the underlying ₹70 distributor acquisition price remains the reference point.
